Print

KaloBios Pharmaceuticals, Inc. Initiates Phase 2 Study With KB003 Humaneered™ Monoclonal Antibody in Severe Asthma  
9/12/2012 10:31:59 AM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company’s anti-GM-CSF Humaneered™ monoclonal antibody, in subjects with severe asthma uncontrolled by corticosteroids.
//-->